Stay updated with breaking news from Seika university. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ad hoc announcement pursuant to Art. 53 LR Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients ....
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data suggest a new strategy for the management of TRS patients ....
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): MiscellaneousNewron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry 28.03.2023 / 12:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Newron presen. ....